Drug-resistant tuberculosis in 2017: At a crossroads

Published Date:

01/31/2019

Source:

Lancet Respir Med

Authors:

Dowdy DW, Theron G, Tornheim JA, Kendall EA

External link

Original Article

In this issue of The Lancet Respiratory Medicine, Dheda and colleagues present one of the most comprehensive pictures to date of the global epidemic of drug-resistant tuberculosis (DR TB).1 This comes at a time of increasing awareness of antimicrobial resistance as a global threat2 – and TB has had a 50-year head start in developing resistance to current first-line therapy. In reading about such phenomena as compensatory mutations, increasing prevalence of incurable TB, and widespread transmission of DR TB, it is easy to become disheartened. If – as suggested in modeling studies3 and recently demonstrated in KwaZulu-Natal, South Africa4 – the majority of new multidrug-resistant (MDR) and extensively drug-resistant TB cases now reflect transmission in communities rather than acquisition during treatment – is there any hope for preventing the eventual replacement of all TB by drug-resistant strains?

Events

«

January 2020

»
S
M
T
W
T
F
S
·
·
·
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
·

Projects

Impact of diabetes on TB treatment outcomes...

This is a study to prospectively enroll and follow TB patients co-infected with diabetes and TB patients without diabetes...

Read More

Modeling the impact of spatially targeted TB...

We have developed transmission models to understand the impact of TB vaccination strategies that target hotspots of...

Read More

TB Modeling and Analysis Consortium (TB MAC)

Dr. Dowdy serves on the steering committee of an international consortium of TB modelers that aims to improve approaches to TB...

Read More

Modeling to improve TB decision-making in the...

We are part of a large consortium that is constructing epidemic and economic models of TB and HIV in collaboration with the U.S....

Read More

ACTG trial A5343

Phase 2 safety study of bedaquiline and delamanid for the treatment of MDR-TB in South Africa

Read More